The second strategy utilizes dual targeting of PRMT5 and BCL-2, using GSK-591 and venetoclax, that exhibits potent anti-tumor efficacy and induction of apoptosis across a wide range of lymphomas. The gene discussed is BCL2; the disease is lymphoma.